Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

PHASE3CompletedINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

May 2, 2016

Primary Completion Date

March 24, 2017

Study Completion Date

March 24, 2017

Conditions
Erosive Esophagitis
Interventions
DRUG

CJ-12420 100mg QD

CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.

DRUG

Esomeprazole 40mg

Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.

DRUG

CJ-12420 50mg QD

CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY